The Department of Medicine at UConn Health has a long history of conducting and supporting clinical research in diverse subspecialties. Our mission is to provide expanded opportunities for clinical research to our faculty and improve the quality and efficacy of treatments available to our patients.
Our Team:
Mallory Edrich – Research Nurse & Study Coordinator
Nicole Glidden – Clinical Research Assistant II & Study Coordinator
Contact Us:
Phone – 860-679-8511
Email – DOMClinicalResearch@uchc.edu
Are you an Investigator looking for help with a Clinical Research Study? See our Resources page!
Our Current Studies:
| Title: | Testing Novel Treatment Approaches for Patients Affected by Hypothyroidism |
| Principal Investigator: | Dr. Francesco Celi |
| Description: | Our preliminary research data suggest that patients with hypothyroidism, especially those post-thyroidectomy surgery, develop weight gain and increase in cholesterol changes that can be prevented or minimized with combination therapy of synthetic T3 (LT3) and T4 (LT4). The study’s goal is to closely examine this phenomenon and help patients reduce their body weight, serum cholesterol, and improve their quality of life. Eligible study participants are those who are 18 and over and on stable thyroid replacement therapy. They will receive free outpatient care for hypothyroidism, study medications, and thyroid hormone and cholesterol lipid analyses for the duration of the study. |
| Classification: | Endocrinology |
| Eligibility Criteria: | Check with study contact |
| How to Contact: | Telephone: 860-679-8511 or Email: DOMClinicalResearch@uchc.edu |
| Enrollment Status/Comments: | Enrolling/recruiting. For current recruitment status, please check with study contact. |
| Title: | A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF) |
| Principal Investigator: | Dr. Ameer Rasheed |
| Description: | The Sponsor is developing AP01 (also referred to in this document as the “study drug”) for use in the treatment of Progressive Pulmonary Fibrosis. AP01 is an experimental drug that we hypothesize may slow your PPF symptoms. You will inhale the study drug using the eFlow® Nebulizer System. The nebulizer used to deliver AP01 is approved in Europe, but is an investigational device for use in the United States and Canada (not approved by FDA or Health Canada). |
| Classification: | Breathing and Lung |
| Eligibility Criteria: | Check with study contact |
| How to Contact: | Telephone: 860-679-8511 or Email: DOMClinicalResearch@uchc.edu |
| Enrollment Status/Comments: | Enrolling/recruiting. For current recruitment status, please check with study contact. |
| Title: | A RANDOMIZED, DOUBLE-BLIND, FOUR-ARM ACTIVE AND PLACEBO-CONTROLLED DOSE-FINDING TRIAL TO EVALUATE THE EFFICACY, TOLERABILITY, SAFETY AND DOSE RESPONSE OF LYT-100 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) |
| Principal Investigator: | Dr. Ameer Rasheed |
| Description: | This study is a randomized, double-blind, being conducted at centers globally to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in 240 treatment naïve adult patients with IPF = 40 years in age. Patients will be randomized in a ratio of 1:1:1:1 to receive treatment of LYT-100, pirfenidone, or placebo to be taken daily for up to 183 days (26 week treatment period) with the primary outcome of Rate of decline in Forced Vital Capacity (FVC; in mL) over 26 weeks. Secondary endpoints, including spirometry, inflammatory biomarkers, and patient-reported outcomes will also be evaluated. |
| Classification: | Breathing and Lung |
| Eligibility Criteria: | Check with study contact |
| How to Contact: | Telephone: 860-679-8511 or Email: DOMClinicalResearch@uchc.edu |
| Enrollment Status/Comments: | Enrolling/recruiting. For current recruitment status, please check with study contact. |